Related Experiment Video

Updated: Feb 24, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

574

Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning

Maya Halabi Tawil1, Rana El Khoury1, Roland Tomb1

  • 1Department of Dermatology, School of Medicine, Saint-Joseph University, Hotel Dieu de France University Hospital and Medical Center, Beirut, Lebanon.

International Journal of Trichology
|August 26, 2017
PubMed

Insights

Nilotinib, a tyrosine kinase inhibitor (TKI), can cause skin side effects like keratosis pilaris and alopecia. This report details a unique case of nilotinib-induced keratosis pilaris combined with alopecia areata, highlighting a new potential adverse reaction.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) are crucial in cancer therapy, offering good tolerability.
  • Cutaneous side effects from TKIs can impact patient compliance and treatment adherence.
  • Nilotinib, a second-generation TKI, is associated with various dermatological adverse events, including alopecia.
Keywords:
Alopecia areatachronic myelogenous leukemiakeratosis pilarisnilotinib

More Related Videos

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.5K
Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ10:05

Stimulation of Stem Cell Niches and Tissue Regeneration in Mouse Skin by Switchable Protoporphyrin IX-Dependent Photogeneration of Reactive Oxygen Species In Situ

Published on: May 8, 2020

2.3K

Related Concept Videos

Accessory Structures of the Skin: Hair Growth and Types01:20

Accessory Structures of the Skin: Hair Growth and Types

Hair growth begins with the production of keratinocytes by the basal cells of the hair bulb. As new cells are deposited at the hair bulb, the hair shaft is pushed through the follicle toward the surface. Keratinization is completed as the cells are pushed to the skin surface to form the shaft of hair that is externally visible. The external hair is completely dead and composed entirely of keratin. Hair can be cut or shaven without damaging the hair structure because the cut is superficial. Most...
2.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
591